title: A HPLC-fluorescence method for the quantification of abiraterone in plasma from patients with metastatic castration-resistant prostate cancer.
abstract: Abiraterone acetate is an oral prodrug of abiraterone, a selective inhibitor of CYP17, used for patients with metastatic castration-resistant prostate cancer (mCRPC). To date, a single liquid chromatographic-tandem mass spectroscopy method has been reported to assay abiraterone concentration in plasma from mCRPC patients. The aim of this study was to develop a simple and sensitive high performance liquid chromatographic (HPLC) method with fluorescence detection for quantification of abiraterone in plasma from mCRPC patients. After protein precipitation with acetonitrile and a liquid-liquid extraction with diethyl ether, abiraterone, and hydroxy-itraconazole (internal standard) were separated on a C8 Xterra(®) MS column using a mobile phase of acetonitrile and glycine buffer 88.4 mM (pH 9.0) (60:40, v/v). Samples were eluted isocratically at a flow rate of 0.9 ml/min throughout an 11-min run. Fluorescence wavelengths' excitation and emission were 255 and 373 nm, respectively. The calibration was linear in the range 1.75-50 ng/ml. Inter- and intraday imprecision were less than 3.5 and 7%, respectively. This method is simple, sensitive, and selective. This analytical method was successfully applied to determine the steady-state plasma exposure to abiraterone in mCRPC patients. This method can be used in routine clinical practice to monitor plasma abiraterone concentrations in mCRPC patients.
authors: Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France.
authors: Tiphaine
authors: T
authors: Belleville
authors: Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France. Electronic address: noe.gaelle@gmail.com.
authors: Gaëlle
authors: G
authors: Noé
authors: Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Service de Cancérologie médicale, Paris, France.
authors: Olivier
authors: O
authors: Huillard
authors: Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France; UMR8638 CNRS, Faculté de Pharmacie, Université Paris Descartes, PRES Sorbonne Paris Cité, Paris, France.
authors: Audrey
authors: A
authors: Thomas-Schoemann
authors: Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France; UMR8638 CNRS, Faculté de Pharmacie, Université Paris Descartes, PRES Sorbonne Paris Cité, Paris, France.
authors: Michel
authors: M
authors: Vidal
authors: Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Service de Cancérologie médicale, Paris, France; Institut Cochin, INSERM U 1016, CNRS UMR8104, CARPEM, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
authors: François
authors: F
authors: Goldwasser
authors: Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Service de Cancérologie médicale, Paris, France; Institut Cochin, INSERM U 1016, CNRS UMR8104, CARPEM, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
authors: Jerome
authors: J
authors: Alexandre
authors: Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France.
authors: Benoit
authors: B
authors: Blanchet
mesh_terms: D000736:Androstenes / Q000008:administration & dosage / Q000097:blood*; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000097:blood* / Q000188:drug therapy
chemical_list: D000736:Androstenes; C089740:abiraterone
keywords: Abiraterone; Fluorescence detection; HPLC; Prostate cancer; Therapeutic drug monitoring